Atorvastatin attenuates bleomycin-induced pulmonary fibrosis via suppressing iNOS expression and the CTGF (CCN2)/ERK signaling pathway

International Journal of Molecular Sciences

Volumn 14, Issue 12, 2013, Pages 24476-24491

  Zhu, Bo ^a   Ma, Ai Qun ^a   Yang, Lan ^a   Dang, Xiao Min ^a  

^a XI'AN JIAOTONG UNIVERSITY   (China)

Author keywords

Atorvastatin; CTGF (CCN2); ERK; iNOS; Pulmonary fibrosis

Indexed keywords

ATORVASTATIN; BLEOMYCIN; COLLAGEN; CONNECTIVE TISSUE GROWTH FACTOR; HYDROXYPROLINE; MALONALDEHYDE; MITOGEN ACTIVATED PROTEIN KINASE; NITRIC OXIDE SYNTHASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DOWN REGULATION; HISTOLOGY; LUNG FIBROSIS; MALE; NONHUMAN; OXIDATIVE STRESS; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RAT; SIGNAL TRANSDUCTION; WESTERN BLOTTING;

ANIMALS; BLEOMYCIN; BODY WEIGHT; COLLAGEN; CONNECTIVE TISSUE GROWTH FACTOR; DOWN-REGULATION; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; HEPTANOIC ACIDS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYDROXYPROLINE; MALE; MALONDIALDEHYDE; NITRIC OXIDE; NITRIC OXIDE SYNTHASE TYPE II; PHOSPHORYLATION; PULMONARY FIBROSIS; PYRROLES; RATS; RATS, SPRAGUE-DAWLEY; SIGNAL TRANSDUCTION;

EID: 84890451672     PISSN: 16616596     EISSN: 14220067     Source Type: Journal    
DOI: 10.3390/ijms141224476     Document Type: Article

References (54)

1. Selman, M.; Thannickal, V.J.; Pardo, A.; Zisman, D.A.; Martinez, F.J.; Lynch, J.P., 3rd. Idiopathic pulmonary fibrosis: Pathogenesis and therapeutic approaches. Drugs 2004, 64, 405-430.
2. Kim, D.S. Acute exacerbations in patients with idiopathic pulmonary fibrosis. Respir. Res. 2013, 14, 86.
3. Cottin, V. Changing the idiopathic pulmonary fibrosis treatment approach and improving patient outcomes. Eur. Respir. Rev. 2012, 21, 161-167.
4. Raghu, G.; Chang, J. Idiopathic pulmonary fibrosis: Current trends in management. Clin. Chest Med. 2004, 25, 621-636.
5. Maher, T.M. Idiopathic pulmonary fibrosis: Pathobiology of novel approaches to treatment. Clin. Chest Med. 2012, 33, 69-83.
6. Antoniou, K.M.; Margaritopoulos, G.A.; Siafakas, N.M. Pharmacological treatment of idiopathic pulmonary fibrosis: From the past to the future. Eur. Respir. Rev. 2013, 22, 281-291.
7. Rahman, I.; Skwarska, E.; Henry, M.; Davis, M.; O'Connor, C.M.; FitzGerald, M.X.; Greening, A.; MacNee, W. Systemic and pulmonary oxidative stress in idiopathic pulmonary fibrosis. Free Radic. Biol. Med. 1999, 27, 60-68.
8. Kinnula, V.L.; Fattman, C.L.; Tan, R.J.; Oury, T.D. Oxidative stress in pulmonary fibrosis: A possible role for redox modulatory therapy. Am. J. Respir. Crit. Care Med. 2005, 172, 417-422.
9. Daniil, Z.D.; Papageorgiou, E.; Koutsokera, A.; Kostikas, K.; Kiropoulos, T.; Papaioannou, A.I.; Gourgoulianis, K.I. Serum levels of oxidative stress as a marker of disease severity in idiopathic pulmonary fibrosis. Pulm. Pharmacol. Ther. 2008, 21, 26-31.
10. Kliment, C.R.; Englert, J.M.; Gochuico, B.R.; Yu, G.; Kaminski, N.; Rosas, I.; Oury, T.D.; Oxidative stress alters syndecan-1 distribution in lungs with pulmonary fibrosis. J. Biol. Chem. 2009, 284, 3537-3545.
11. Chitra, P.; Saiprasad, G.; Manikandan, R.; Sudhandiran, G. Berberine attenuates bleomycin induced pulmonary toxicity and fibrosis via suppressing NF-κB dependant TGF-β activation: A biphasic experimental study. Toxicol. Lett. 2013, 219, 178-193.
12. Fubini, B.; Hubbard, A. Reactive oxygen species (ROS) and reactive nitrogen species (RNS) generation by silica in inflammation and fibrosis. Free Radic. Biol. Med. 2003, 34, 1507-1516.
13. Bargagli, E.; Olivieri, C.; Bennett, D.; Prasse, A.; Muller-Quernheim, J.; Rottoli, P. Oxidative stress in the pathogenesis of diffuse lung diseases: A review. Respir. Med. 2009, 103, 1245-1256.
14. Paredi, P.; Kharitonov, S.A.; Barnes, P.J. Analysis of expired air for oxidation products. Am. J. Respir. Crit. Care Med. 2002, 166, S31-S37.
15. Barnes, P.J.; Hansel, T.T. Prospects for new drugs for chronic obstructive pulmonary disease. Lancet 2004, 364, 985-996.
16. Kalayarasan, S.; Sriram, N.; Sudhandiran, G. Diallyl sulfide attenuates bleomycin-induced pulmonary fibrosis: Critical role of iNOS, NF-kappaB, TNF-alpha and IL-1beta. Life Sci. 2008, 82, 1142-1153.
17. Minder, C.M.; Blaha, M.J.; Horne, A.; Michos, E.D.; Kaul, S.; Blumenthal, R.S. Evidence-based use of statins for primary prevention of cardiovascular disease. Am. J. Med. 2012, 125, 440-446.
18. Davignon, J. Pleiotropic effects of pitavastatin. Br. J. Clin. Pharmacol. 2012, 73, 518-535.
19. Athyros, V.G.; Kakafika, A.I.; Tziomalos, K.; Karagiannis, A.; Mikhailidis, D.P. Pleiotropic effects of statins-clinical evidence. Curr. Pharm. Des. 2009, 15, 479-489.
20. Mikael, L.G.; Rozen, R. Homocysteine modulates the effect of simvastatin on expression of ApoA-I and NF-kappaB/iNOS. Cardiovasc. Res. 2008, 80, 151-158.
21. Araújo, F.A.; Rocha, M.A.; Mendes, J.B.; Andrade, S.P. Atorvastatin inhibits inflammatory angiogenesis in mice through down regulation of VEGF, TNF-alpha and TGF-beta1. Biomed. Pharmacother. 2010, 64, 29-34.
22. Shyamsundar, M.; McKeown, S.T.; O'Kane, C.M.; Craig, T.R.; Brown, V.; Thickett, D.R.; Matthay, M.A.; Taggart, C.C.; Backman, J.T.; Elborn, J.S., et al. Simvastatin decreases lipopolysaccharide-induced pulmonary inflammation in healthy volunteers. Am. J. Respir. Crit. Care Med. 2009, 179, 1107-1114.
23. Massaro, M.; Zampolli, A.; Scoditti, E.; Carluccio, M.A.; Storelli, C.; Distante, A.; de Caterina, R. Statins inhibit cyclooxygenase-2 and matrix metalloproteinase-9 in human endothelial cells: Anti-angiogenic actions possibly contributing to plaque stability. Cardiovasc. Res. 2010, 86, 311-320.
24. Jiang, C.; Huang, H.; Liu, J.; Wang, Y.; Lu, Z.; Xu, Z. Fasudil, a rho-kinase inhibitor, attenuates bleomycin-induced pulmonary fibrosis in mice. Int. J. Mol. Sci. 2012, 13, 8293-8307.
25. Brigstock, D.R.; Goldschmeding, R.; Katsube, K.I.; Lam, S.C.; Lau, L.F.; Lyons, K.; Naus, C.; Perbal, B.; Riser, B.; Takigawa, M., et al. Proposal for a unified CCN nomenclature. Mol. Pathol. 2003, 56, 127-128.
26. Leask, A. Possible strategies for anti-fibrotic drug intervention in scleroderma. J. Cell Commun. Signal 2011, 5, 125-129.
27. Mason, R.M. Fell-Muir lecture: Connective tissue growth factor (CCN2)-A pernicious and pleiotropic player in the development of kidney fibrosis. Int. J. Exp. Pathol. 2013, 94, 1-16.
28. White, E.S.; Lazar, M.H.; Thannickal, V.J. Pathogenetic mechanisms in usual interstitial pneumonia/idiopathic pulmonary fibrosis. J. Pathol. 2003, 201, 343-354.
29. Gothelf, A.; Mir, L.M.; Gehl, J. Electrochemotherapy: Results of cancer treatment using enhanced delivery of bleomycin by electroporation. Cancer Treat Rev. 2003, 29, 371-387.
30. Azambuja, E.; Fleck, J.F.; Batista, R.G.; Menna Barreto, S.S. Bleomycin lung toxicity: Who are the patients with increased risk? Pulm. Pharmacol. Ther. 2005, 18, 363-366.
31. Moeller, A.; Ask, K.; Warburton, D.; Gauldie, J.; Kolb, M. The bleomycin animal model: A useful tool to investigate treatment options for idiopathic pulmonary fibrosis? Int. J. Biochem. Cell Biol. 2008, 40, 362-382.
32. Wan, Y.Y.; Tian, G.Y.; Guo, H.S.; Kang, Y.M.; Yao, Z.H.; Li, X.L.; Liu, Q.H.; Lin, D.J. Endostatin, an angiogenesis inhibitor, ameliorates bleomycin-induced pulmonary fibrosis in rats. Respir. Res. 2013, 14, 56.
33. Chaudhary, N.I.; Schnapp, A.; Park, J.E. Pharmacologic differentiation of inflammation and fibrosis in the rat bleomycin model. Am. J. Respir. Crit. Care Med. 2006, 173, 769-776.
34. Mouratis, M.A.; Aidinis, V. Modeling pulmonary fibrosis with bleomycin. Curr. Opin. Pulm. Med. 2011, 17, 355-361.
35. Cheresh, P.; Kim, S.J.; Tulasiram, S.; Kamp, D.W. Oxidative stress and pulmonary fibrosis. Biochim. Biophys. Acta 2013, 1832, 1028-1040.
36. Tsutsui, M.; Shimokawa, H.; Otsuji, Y.; Yanagihara, N. Pathophysiological relevance of NO signaling in the cardiovascular system: novel insight from mice lacking all NO synthases. Pharmacol. Ther. 2010, 128, 499-508.
37. Scotton, C.J.; Chambers, R.C. Molecular targets in pulmonary fibrosis: The myofibroblast in focus. Chest 2007, 132, 1311-1121.
38. Phanish, M.K.; Winn, S.K.; Dockrell, M.E. Connective tissue growth factor-(CTGF,CCN2)-A marker, mediator and therapeutic target for renal fibrosis. Nephron Exp. Nephrol. 2010, 114, e83-e92.
39. Gressner, O.A.; Gressner, A.M. Connective tissue growth factor: A fibrogenic master switch in fibrotic liver diseases. Liver Int. 2008, 28, 1065-1079.
40. Ponticos, M.; Holmes, A.M.; Shi-Wen, X.; Leoni, P.; Khan, K.; Rajkumar, V.S.; Hoyles, R.K.; Bou-Gharios, G.; Black, C.M.; Denton, C.P., et al. Pivotal role of connective tissue growth factor in lung fibrosis: MAPK-dependent transcriptional activation of type I collagen. Arthritis Rheum. 2009, 60, 2142-2155.
41. Tannheimer, S.L.; Wright C.D., Salmon, M. Combination of roflumilast with a beta-2 adrenergic receptor agonist inhibits proinflammatory and profibrotic mediator release from human lung fibroblasts. Respir. Res. 2012, 13, 28.
42. Rodrigues-Díez, R.; Lavoz, C.; Rayego-Mateos, S.; Civantos, E.; Rodríguez-Vita, J.; Mezzano, S.; Ortiz, A.; Egido, J.; Ruiz-Ortega, M. Statins inhibit angiotensin II/Smad pathway and related vascular fibrosis, by a TGF-β-independent process. PLoS One 2010, 5, e14145.
43. Galuppo, M.; Esposito, E.; Mazzon E.; di Paola, R.; Paterniti, I.; Impellizzeri, D.; Cuzzocrea, S. MEK inhibition suppresses the development of lung fibrosis in the bleomycin model. Naunyn-Schmiedebergs Arch. Pharmacol. 2011, 384, 21-37.
44. Antoniou, K.M.; Margaritopoulos, G.A.; Soufla, G.; Symvoulakis, E.; Vassalou, E.; Lymbouridou, R.; Samara, K.D.; Kappou, D.; Spandidos, D.A.; Siafakas, N.M. Expression analysis of Akt and MAPK signaling pathways in lung tissue of patients with idiopathic pulmonary fibrosis (IPF). J. Recept. Signal Transduct. Res. 2010, 30, 262-269.
45. Adamali, H.I.; Maher, T.M. Current and novel drug therapies for idiopathic pulmonary fibrosis. Drug Des. Devel. Ther. 2012, 6, 261-272.
46. Whelan, T.P. Lung transplantation for interstitial lung disease. Clin. Chest Med. 2012, 33, 179-189.
47. McShane, P.J.; Garrity, E.R., Jr. Minimization of immunosuppression after lung transplantation: Current trends. Transpl. Int. 2009, 22, 90-95.
48. Strieter, R.M.; Mehrad, B. New mechanisms of pulmonary fibrosis. Chest 2009, 136, 1364-1370.
49. Richeldi, L. Assessing the treatment effect from multiple trials in idiopathic pulmonary fibrosis. Eur. Respir. Rev. 2012, 21, 147-151.
50. Nadrous, H.F.; Ryu, J.H.; Douglas, W.W.; Decker, P.A.; Olson, E.J. Impact of angiotensin-converting enzyme inhibitors and statins on survival in idiopathic pulmonary fibrosis. Chest 2004, 126, 438-446.
51. Alexeeff, S.E.; Litonjua, A.A.; Sparrow, D.; Vokonas, P.S.; Schwartz, J. Statin use reduces decline in lung function: VA Normative Aging Study. Am. J. Respir. Crit. Care Med. 2007, 176, 742-747.
52. Yang, J.; Song, T.B.; Zhao, Z.H.; Qiu, S.D.; Hu, X.D.; Chang, L. Vasoactive intestinal peptide protects against ischemic brain damage induced by focal cerebral ischemia in rats. Brain Res. 2011, 1398, 94-101.
53. Punithavathi, D.; Venkatesan, N.; Babu, M. Curcumin inhibition of bleomycin-induced pulmonary fibrosis in rats. Br. J. Pharmacol. 2000, 131, 169-172.
54. Edwards, C.A.; O'Brien, W.D., Jr. Modified assay for determination of hydroxyproline in a tissue hydrolyzate. Clin. Chim. Acta 1980, 104, 161-167.